We used propensity-score matching to adjust for differences between users and control for each dosage, and compared serum chemical data including serum sodium, potassium, uric acid, creatinine and urea nitrogen.
Logistic regression adjusting for age as categorical variable in one-year age groups was used to calculate p-values for differences in the presence of comorbid diagnoses between users and the control group.
Most other cardiovascular comorbidities showed no differences between MPH users and controls.
There were no statistically significant differences for all covariates between trichlormethiazide users and controls for both doses.
Differences in the presence of comorbid diagnoses between MPH users and controls were tested by logistic regression.
There were no statistically significant differences in all covariates (age, sex, comorbid diseases, past drugs, and current antihypertensive drugs) between trichlormethiazide users and controls for both doses.
A recent meta-analysis has compared the eGFR values between lithium users and controls from studies published up to 2010 [ 8].
However, one meta-analysis by Waller and Gilbody [ 27] indicated that there was no significant difference between CCBT users and controls, but this meta-analysis had substantial diagnostic heterogeneity (two depression-specific studies and seven studies specific to other disorders).
We found only a small number of children and adolescents with a diagnosis of bipolar affective disorder in our study, but still there were statistically significant differences between MPH users and controls.
